Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities
Year: 2024
Type: review
Abstract: With full FDA approval and Centers for Medicare & Medicaid Services coverage of lecanemab and donanemab, a growing number of practices are offering anti-amyloid immunotherapy to appropriate patients with cognitive impairment or mild dementia due to amyloid-positive Alzheimer disease. The goal of this article is to provide updated practical considerations for radiologists, including implementation of MR imaging protocols, workflows, and reporting and communication practices relevant to anti-amyloid immunotherapy and monitoring for amyloid-related imaging abnormalities (ARIA). On the basis of consensus discussion within an expanded American Society of Neuroradiology (ASNR) Alzheimer, ARIA, and Dementia Study Group, our purpose is the following: 1) summarize the FDA guidelines for the evaluation of radiographic ARIA; 2) review the 3 key MRI sequences for ARIA monitoring and standardized imaging protocols on the basis of ASNR-industry collaborations; 3) provide imaging recommendations for 3 key patient scenarios; 4) highlight the role of the radiologist in the care team for this population; 5) discuss implementation of MRI protocols to detect ARIA in diverse practice settings; and 6) present the results of the 2023 ASNR international neuroradiologist practice survey on dementia and ARIA imaging.
DOI: 10.3174/ajnr.a8469
Authors: Petrice M. Cogswell, Trevor J. Andrews, Jerome A. Barakos, Frederik Barkhof, Suzie Bash, Marc Daniel Benayoun, Gloria C. Chiang, Ana M. Franceschi, Clifford R. Jack, Jay J. Pillai, Tina Young Poussaint, Cyrus A. Raji, Vijay K. Ramanan, Jody Tanabe, Lawrence Tanenbaum, Christopher T. Whitlow, Fang F. Yu, Greg Zaharchuk, Michael Zeinah, Tammie S. Benzinger
Institutions: Boston Children's Hospital, Mayo Clinic, Washington University in St. Louis, California Pacific Medical Center, UCL Queen Square Institute of Neurology, University College London, Amsterdam UMC Location Vrije Universiteit Amsterdam, Wake Forest University Health Sciences, Wake Forest University, Weill Cornell Medicine, Weill Cornell Medical Center, Northwell Health, University of Colorado Hospital, The University of Texas Southwestern Medical Center, Stanford Health Care, Stanford Medicine, Stanford University
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Awards: DIAN-TU: Next Generation Prevention Trial, Dominantly Inherited Alzheimer Network, DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIA, Healthy Aging and Senile Dementia, Dominantly Inherited Alzheimer Network, Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention Trial, DIAN-TU: Next Generation Prevention Trial, Alzheimer's Disease Research Center, Antecedent Biomarkers for Alzheimer Disease: The Adult Children Study, Alzheimer's Disease Research Center, DIAN-TU: Tau Next Generation Prevention Trial
OpenAlex ID: W4401811647